SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
SOPHiA GENETICS (SOPH) has globally launched MSK-IMPACT® powered with SOPHiA DDM™, a comprehensive genomic profiling application developed in collaboration with Memorial Sloan Kettering Cancer Center. The solution enables organizations worldwide to access advanced tumor profiling technologies with high accuracy and efficiency. The platform demonstrates exceptional performance with 99.3% positive agreement for SNV/Indel detection and 94.6% for CNV detection. SOFIVA GENOMICS in Taiwan is among the first adopters, expanding their tumor profiling capabilities. The workflow takes approximately five days from DNA extraction to final report, integrating OncoKB™ for enhanced analytical insights.
SOPHiA GENETICS (SOPH) ha lanciato a livello globale MSK-IMPACT® potenziato con SOPHiA DDM™, un'applicazione completa di profilazione genomica sviluppata in collaborazione con il Memorial Sloan Kettering Cancer Center. La soluzione consente a organizzazioni in tutto il mondo di accedere a tecnologie avanzate di profilazione tumorale con alta precisione ed efficienza. La piattaforma dimostra prestazioni eccezionali con un 99,3% di accordo positivo per il rilevamento di SNV/Indel e un 94,6% per il rilevamento di CNV. SOFIVA GENOMICS a Taiwan è tra i primi adottanti, ampliando le proprie capacità di profilazione tumorale. Il processo richiede circa cinque giorni dall'estrazione del DNA al rapporto finale, integrando OncoKB™ per approfondimenti analitici migliorati.
SOPHiA GENETICS (SOPH) ha lanzado a nivel mundial MSK-IMPACT® potenciado con SOPHiA DDM™, una aplicación integral de perfilado genómico desarrollada en colaboración con el Memorial Sloan Kettering Cancer Center. La solución permite a organizaciones de todo el mundo acceder a tecnologías avanzadas de perfilado tumoral con alta precisión y eficiencia. La plataforma demuestra un rendimiento excepcional con un 99.3% de acuerdo positivo para la detección de SNV/Indel y un 94.6% para la detección de CNV. SOFIVA GENOMICS en Taiwán se encuentra entre los primeros adoptantes, ampliando sus capacidades de perfilado tumoral. El flujo de trabajo toma aproximadamente cinco días desde la extracción de ADN hasta el informe final, integrando OncoKB™ para obtener información analítica mejorada.
SOPHiA GENETICS (SOPH)는 전 세계적으로 SOPHiA DDM™로 강화된 MSK-IMPACT®를 출시했습니다. 이 통합 유전체 프로파일링 애플리케이션은 Memorial Sloan Kettering Cancer Center와 협력하여 개발되었습니다. 이 솔루션은 전 세계의 조직이 높은 정확성과 효율성으로 첨단 종양 프로파일링 기술에 접근할 수 있도록 합니다. 이 플랫폼은 SNV/Indel 탐지에서 99.3%의 긍정적인 일치를 나타내며, CNV 탐지에서 94.6%의 성능을 보여줍니다. 대만에 있는 SOFIVA GENOMICS는 종양 프로파일링 기능을 확장하는 최초의 사용자인 중 하나입니다. 프로세스는 DNA 추출에서 최종 보고서까지 약 5일이 소요되며, OncoKB™를 통합하여 향상된 분석 통찰력을 제공합니다.
SOPHiA GENETICS (SOPH) a lancé mondialement MSK-IMPACT® alimenté par SOPHiA DDM™, une application complète de profilage génomique développée en collaboration avec le Memorial Sloan Kettering Cancer Center. La solution permet aux organismes du monde entier d'accéder à des technologies avancées de profilage tumoral avec une grande précision et efficacité. La plateforme démontre des performances exceptionnelles avec un 99,3% d'accord positif pour la détection des SNV/Indel et 94,6% pour la détection des CNV. SOFIVA GENOMICS à Taïwan fait partie des premiers utilisateurs, élargissant ses capacités de profilage tumoral. Le flux de travail prend environ cinq jours, de l'extraction de l'ADN au rapport final, intégrant OncoKB™ pour des insights analytiques améliorés.
SOPHiA GENETICS (SOPH) hat weltweit MSK-IMPACT® mit SOPHiA DDM™ eingeführt, eine umfassende Anwendung für genomisches Profiling, die in Zusammenarbeit mit dem Memorial Sloan Kettering Cancer Center entwickelt wurde. Die Lösung ermöglicht es Organisationen auf der ganzen Welt, mit hoher Genauigkeit und Effizienz auf fortschrittliche Tumorprofilierungstechnologien zuzugreifen. Die Plattform zeigt eine außergewöhnliche Leistung mit 99,3% positiver Übereinstimmung bei der SNV/Indel-Erkennung und 94,6% bei der CNV-Erkennung. SOFIVA GENOMICS in Taiwan gehört zu den ersten Nutzern und erweitert ihre Tumorprofilierungsfähigkeiten. Der Arbeitsablauf dauert etwa fünf Tage von der DNA-Extraktion bis zum endgültigen Bericht und integriert OncoKB™ für verbesserte analytische Einblicke.
- High accuracy validation results: 99.3% agreement for SNV/Indel detection
- Efficient workflow completion in approximately 5 days
- Integration with MSK's OncoKB™ knowledge base enhancing analytical capabilities
- Early adoption by SOFIVA GENOMICS demonstrates market traction
- None.
Insights
The launch of MSK-IMPACT® powered with SOPHiA DDM™ represents a significant advancement in precision oncology diagnostics. The platform's impressive validation metrics, including
The platform's ability to enhance MTAP gene detection accuracy is particularly noteworthy, as MTAP deletions are emerging as important biomarkers for targeted therapies. The matched tumor-normal analysis approach significantly reduces false positives in somatic mutation detection, addressing a critical challenge in cancer diagnostics. The expansion into Taiwan through SOFIVA GENOMICS indicates strong commercial potential in the Asian market.
This product launch strengthens SOPHiA GENETICS' market position in the growing precision oncology space. The partnership with Memorial Sloan Kettering Cancer Center, a prestigious institution, adds significant credibility and market value. The platform's global accessibility and decentralized approach could drive substantial market penetration, particularly in underserved regions.
The expansion of SOFIVA GENOMICS' adoption from HRD testing to include both MSK-IMPACT® and MSK-ACCESS® demonstrates successful product ecosystem development and customer retention. The platform's network effect, generating collective intelligence from diverse populations, creates a sustainable competitive advantage and potential for recurring revenue growth through data insights.
Launch of new application enables global access to highly recognized solid tumor profiling assay
"The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine," said Philippe Menu, M.D., PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS. "Following the successful launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we are incredibly excited to further build on our excellent collaboration with MSK. Launching this application is a powerful step in our vision to decentralize access to advanced tumor profiling technologies, making these capabilities more widely available, especially in underserved populations."
Kojo S. J. Elenitoba-Johnson, M.D., Chair of the Department of Pathology and Lab Medicine at MSK, added, "We share a vision with SOPHiA GENETICS to advance precision medicine and to make our leading tests more accessible to patients around the world."
Through MSK-IMPACT® powered with SOPHiA DDM™, organizations can process more precise oncology analysis by enhancing the accuracy of somatic mutation detection, including in genes that are highly relevant for the current pharmaceutical industry R&D pipelines, such as MTAP. The matched tumor-normal analysis approach allows clinicians and researchers to detect somatic mutations more confidently, minimizing the risk of misclassifying germline variants as tumor-specific. Additionally, institutions benefit from the global collective intelligence created by SOPHiA GENETICS' network, allowing users to contribute to and draw from a continuously evolving base of real-world data and insights from diverse populations.
SOFIVA GENOMICS, a leading molecular diagnostics company in
Chia-Cheng Hung, General Manager, SOFIVA GENOMICS, commented, "Our partnership with SOPHiA GENETICS has greatly enhanced our ability to provide localized, highly accurate genomic testing. Access to this advanced technology enables us to bring advanced, trusted capabilities and further our progress on cancer research in
MSK-IMPACT® powered with SOPHiA DDM™ enables a more efficient workflow, with the entire process from DNA extraction to final report taking approximately five days. Clinicians and researchers benefit from access to OncoKB™, MSK's Precision Oncology Knowledge Base, which further enhances the interpretive power of the SOPHiA DDM™ analysis through data-driven, actionable insights. In-house analytical validation results for MSK-IMPACT® powered with SOPHiA DDM™ showed high concordance to the single-site MSK-IMPACT® test, achieving:
99.3% positive percent agreement (PPA) for SNV/Indel detection94.6% PPA for copy number variant (CNV) detection99.4% overall percent agreement (OPA) for microsatellite instability (MSI) detection98.8% OPA for tumor mutational burden (TMB) detection.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. Concordance results based on analytic assessment of RUO products.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-msk-impact-powered-with-sophia-ddm-at-amp-2024-302312292.html
SOURCE SOPHiA GENETICS
FAQ
What are the accuracy rates of MSK-IMPACT powered with SOPHiA DDM?
How long does the MSK-IMPACT powered with SOPHiA DDM analysis process take?
Who is the first major adopter of SOPHiA GENETICS' MSK-IMPACT platform?
What features does SOPHiA GENETICS' MSK-IMPACT platform include?
